SAEs deemed related to simtuzumab/placebo. As this was a double‐blind study, the SAEs considered related to simtuzumab were recorded for both treatment arms. SAEs related to FOLFIRI were not collected. n = 80, safety analysis set.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.